ATEC
Alphatec Holdings, Inc.
Price as of Jul 20, 2026
ATEC earnings
Alphatec Holdings, Inc. earnings
Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-0.01 | $-0.22 | -2100.0% | $192M | -2.7% |
| Feb 24, 2026 | $0.04 | $0.06 | +50.0% | $213M | +5.3% |
| Oct 30, 2025 | $-0.03 | $0.03 | +200.0% | $197M | -6.1% |
| Jul 31, 2025 | $-0.06 | $0.02 | +133.3% | $186M | +1.6% |
| May 1, 2025 | $-0.12 | $-0.23 | -91.7% | $169M | -5.4% |
| Feb 26, 2025 | $-0.19 | $-0.23 | -21.1% | $177M | +2.3% |
| Oct 30, 2024 | $-0.27 | $-0.28 | -3.7% | $151M | -11.5% |
| Jul 31, 2024 | $-0.26 | $-0.29 | -11.5% | $146M | -1.1% |
| Feb 27, 2024 | $-0.28 | $-0.37 | -32.1% | $138M | +5.3% |
| Aug 3, 2023 | $-0.30 | $-0.43 | -43.3% | $117M | +6.4% |
| May 4, 2023 | $-0.32 | $-0.40 | -25.0% | $109M | +4.2% |
| Feb 28, 2023 | $-0.30 | $-0.33 | -10.0% | $106M | +3.7% |
Earnings call summary
Q1 FY2026 · May 5, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Business is scaling. Surgical revenue up 17%, cases up 21%, surgeons up 23%. EOS Insight evolving into a platform with growth and adoption creating momentum. • Invested in what's working, leaning into the durable growth model. • Strategy focuses on clinical distinction, surgeon adoption, and a strong sales engine. EOS has enabled access to prestigious institutions and is driving case volume and data generation. Valence is fitting into surgical workflow with positive feedback.
Guidance
• Expect total revenue for full year 2026 of approximately $882 million, 15% growth year over year. Surgical revenue approximately $805 million, unchanged from prior guidance, 17% growth. • Expect EOS revenue of approximately $77 million. • Expect adjusted EBITDA of approximately $134 million, 15% margin. • Expect at least $20 million in free cash flow for the full year, second quarter free cash flow expected to approximate zero.
Segment performance
Total revenue was $192 million, up 14% year-over-year. Surgical revenue was $178 million, growing 17%. Cases up 21%, surgeons up 23%. EOS revenue was $14 million for the quarter. Generated $21 million of EBITDA. Total revenue contribution: Surgical was 92.7% ($178M / $192M), EOS was 7.3% ($14M / $192M).
Risks & headwinds
• EOS revenue fell short of quarterly goal due to execution issues in sales, downstream marketing, and support. • Seasonality and weather impacts can affect revenue. • Deceleration in revenue in Q1 with recovery in April but still some unpredictability in recent quarters related to execution flaws in EOS installations.
Analyst Q&A
Q: Regarding 2027 LRP revenue number and consensus,
A: Adjustment to EOS guidance reflects near-term execution issues addressed by adding sales and marketing resources, believing on track to long-range plan.
Q: On pricing per case headwind,
A: Revenue per case decline due to mix of cervical procedures, international business, and biologics attachment rate, expecting flat revenue per procedure for balance of year.
Q: On surgical Q1 performance and sequential,
A: Momentum in distinguishing procedures robust, surge in surgeon additions, April rebounded, confidence in full year plan.
Q: On EOS franchise cadence,
A: Expect EOS to contribute more meaningfully in second half, overall growth in second quarter similar to first quarter.
Q: On EOS execution weakness and impact,
A: EOS execution flaw, not bleeding into other parts of business.
Q: On surgical outlook confidence,
A: Confidence from demand profile of distinguishing procedures and surgeon adoption.
Q: On Valence placements and pull-through,
A: Valence doing as expected, utilized in PTP, trending toward more than target.
Q: On surgeon penetration and volume growth,
A: Strong surge in adoption, utilization rates growing, confidence in full year surgical guide from surgeon demand and procedural adoption.
Q: On EOS thesis,
A: EOS thesis intact, structured data set unique, committed to the strategy
Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-08-04.